Results
Data From Sequenta's Lymphosight Presented
June 20 2012
Sequenta, Inc. announced today that data demonstrating the power of its DNA sequencing-based LymphoSIGHTTM platform for the detection of Minimal Residual Disease (MRD) was presented during the European Hematology Association (EHA) meeting in Amsterdam June 15.
Data from collaborations with researchers at the Comprehensive Cancer Center Universitätsklinik Schleswig-Holstein taken from 120 samples from mantle cell lymphoma (MCL) patients were summarized by Dr. Christiane Pott from Second Medical Department, Comprehensive Cancer Center Universitätsklinik Schleswig-Holstein.
“The LymphoSIGHTTM sequencing method has shown very comparable performance to our ASO-PCR methodology but eliminates the need to develop patient-specific reagents,” said Pott. “MRD detection technologies are having a profound effect on disease management as new clinical paradigms to treat subclinical disease emerge.”
The data presented compares the LymphoSIGHTTM platform with the current standard of care, immunoglobulin heavy-chain allele-specific oligonucleotide polymerase chain reaction (IgH ASO-PCR). Findings included:
· Sequenta technology represents a universal assay capable of achieving sensitivity comparable to IgH ASO-PCR in MCL while avoiding the process of developing patient-specific MRD assays that is required of ASO-PCR.
· The LymphoSIGHTTM method has the ability to follow B cell rearrangements across multiple immune cell receptors.
“Having previously demonstrated the sensitivity advantages of our platform relative to flow cytometry, these results comparing the technology to ASO-PCR underscore the power of this technology as a platform for the detection of MRD,” said Tom Willis, Sequenta’s CEO. “Sequenta is in the process of building a clinical lab that is capable of offering this test commercially in 2013.”
LymphoSIGHTTM utilizes a proprietary assay for the amplification and sequencing of immunoglobulin and T cell receptors, enabling ultra sensitive detection and monitoring of T and B cells. The platform leverages the power of next generation sequencing to detect individual B cells at levels as low as one cell per million white blood cells using a universal reagent set and routinely available blood samples.
Back to top